Determining Paediatric Usual Values for Hormones Dosages by LC-MS/MS

NCT ID: NCT06694415

Last Updated: 2025-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-02

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Liquid chromatography coupled with mass spectrometry (LC-MS/MS) is now the method of choice for steroid hormone analysis, as it enables analyses to be carried out on small-volume samples on a wider range of hormones, with improved specificity compared with immunoassays. Hormone assays currently face a twofold problem: on the one hand, immunoassays are highly dependent on the synthesis of antibody kits manufactured by companies with immunotechnology expertise; on the other hand, these immunoassays may require the use of radioactive products for quantification, generating considerable risks for both staff and environment. There are international recommendations from expert societies (World Anti-Doping Agency, Endocrine society) to develop new, more reliable assay methods, such as LC-MS/MS, and to phase out immuno- and radioassay techniques.

However, changing measurement methods requires the development of reference values to maintain and optimize the management of patients.

The aim of this project is therefore to establish usual values in a paediatric population, through collaboration between the clinical departments of the APHP and the METOMICS laboratory, which has mastered the technology.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, multicentric, non-randomized. The study will be uncontrolled, as it will use subjects considered "healthy" to establish reference values.

Recruitment is planned to take place in hospital consultations at recruiting centers belonging to the AP-HP.

During the blood sample prescribed as part of the follow-up consultation, an additional blood tube will be collected after information, consent and inclusion.

The following acts and procedures will be added as part of the research:

* additional tube, respecting the total volume taken according to weight (maximum volume of 2.7mL);
* Routine circuit for sending and receiving the tube to ensure the relevance of standards established in real life.
* A biological collection will be set up. Pseudonymized data will be collected on a secure REDCap database. The source data will be: Recruiting center; Age; Gender; Pubertal stage if available; Results of blood tests carried out by mass spectrometry as part of this research.

The clinical database will be completed by investigators from the Endocrine Functional Explorations Department at Trousseau Hospital and biologists from the METOMICS Department at Saint-Antoine Hospital. Data will not be processed outside the AP-HP. Data will be kept in an active secured database for the duration of the study and up to 2 years after the last publication, and archived for 15 years.

Mass spectrometry analyses will be carried out under the supervision of Pr Antonin Lamazière, Head of the Clinical Metabolomics Department at Hôpital Saint Antoine. Data from these analyses will be stored in the same clinical laboratory and shared only with/between the principal investigator and the study methodologist.

During the research phase, the collection will be stored at the Clinical Metabolomics Department (METOMICS) laboratory, under the responsibility of Prof. Antonin Lamazière, for 2 years. At the end of the research, the samples will be stored for a maximum of 15 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Control Condition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control individuals below 20 years of age

blood sample with hormone dosages

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patient ≤ 20 years old
* undergoing a blood sample as part of their pathology routine follow-up

Exclusion Criteria

* Any identified or suspected endocrine pathology
* Any acute infectious or inflammatory disorder
Maximum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eloïse Giabicani, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Organizational Affiliation: Assistance Publique - Hôpitaux de Paris (AP-HP en général)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service d'Endocrinologie Pédiatrique-Explorations Fonctionnelles Hôpital Trousseau

Paris, Paris, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Eloïse Giabicani, MD, PhD

Role: CONTACT

+33 (0)1 49 28 66 94

Marie-Pierre Luton, PhD

Role: CONTACT

+33(0) 1 87 89 26 00

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Eloïse Giabicani, MD, PhD

Role: primary

+33 (0)1 49 28 66 94

Marie-Pierre Luton, PhD

Role: backup

+33(0) 1 87 89 26 00

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IDRCB-2024-A01634-43

Identifier Type: OTHER

Identifier Source: secondary_id

APHP240887

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Preterm Infants Fed a Human Milk Fortifier
NCT05551975 NOT_YET_RECRUITING NA
Formula Tolerance of Term Infants
NCT04915937 COMPLETED NA